CD8A and neoplasm: Again, taking AK104 as an example, in addition to targeting co-expressed CD8+ T cells, one arm of AK104 can also target single expressed PD-1+CD8+T or single-expressed CTLA4+ CD4+T cells, which are abundant in the tumor microenvironment and exert optimal anti-tumor activity by covering more effector T cells.